Thursday, May 12, 2022

Halozyme Therapeutics Clears Hart-Scott-Rodino Hurdle

San Diego-based biopharmaceuticals firm Halozyme Therapeutics said today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its proposed acquisition of Antares Pharma has expired. The company said its deal still remains subject to various conditions. Halozyme offered to acquire Antares Pharma for $5.60 per share in cash on April 26th. The deal is worth approximately $960M in total.